False-positive results of galactomannan assays in patients administered glucose-containing solutions

Sci Rep. 2024 Jan 31;14(1):2552. doi: 10.1038/s41598-024-53116-x.

Abstract

Galactomannan (GM) is a polysaccharide cell wall component released by Aspergillus spp., and an immunoenzymatic GM assay is used for the diagnosis of invasive pulmonary aspergillosis. We evaluated the cause of strong positivity for GM in patients with no typical signs of aspergillosis. Repeat assays were performed using different instruments and reagent lots, but there were no differences in results among the assays. Patients with strongly positive GM results were investigated. Medication histories revealed that 14 of 23 patients had been administered total parenteral nutrition solution from one manufacturer and 4 patients had been administered dextrose solution from a different manufacturer before being tested. The results of GM assays conducted on samples of dextrose solution and the glucose fraction of the total parenteral nutrition solution were strongly positive, confirming the causes of the false-positive reactions. We hypothesize that a trace amount of GM was introduced into the glucose-containing solutions because glucoamylase, which is necessary for the saccharification step of glucose synthesis, was derived from Aspergillus niger. To enhance patient care and prevent unnecessary antifungal prescriptions, healthcare providers and manufacturers of healthcare products need to be aware of the possibility of false-positive reactions for GM.

MeSH terms

  • Antigens, Fungal
  • Aspergillosis* / drug therapy
  • Galactose
  • Glucose / therapeutic use
  • Humans
  • Mannans
  • Parenteral Nutrition Solutions
  • Sensitivity and Specificity

Substances

  • galactomannan
  • Mannans
  • Galactose
  • Glucose
  • Parenteral Nutrition Solutions
  • Antigens, Fungal